Fundraising FoxEmbera NeuroTherapeutics
Sudbury, US · 4 known investors
Find your way into Embera NeuroTherapeutics
Sign up to see every warm intro you have to Embera NeuroTherapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Embera NeuroTherapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Clinical-stage specialty pharma developing a combination drug to treat a range of addictions, licensed from LSU Health Sciences Center.
Founders & leadership
RB
Robert B. LinkeExecutive
Board
RB
Ross BarrettBoard director
FH
Franz HeftiBoard director
JB
John BeairdBoard director
JL
Joseph LovettBoard director
Investors · 4
Innovation Catalystlisted by Innovation CatalystBaton Rouge
How we know: Innovation Catalyst's portfolio page · Not right? Tell us
Keiretsu Forumlisted by Keiretsu ForumSan Francisco East Bay · $250K – $2M
How we know: Keiretsu Forum's portfolio page · Not right? Tell us
Louisiana Fundslisted by Louisiana FundsBaton Rouge
How we know: Louisiana Funds's portfolio page · Not right? Tell us
Keiretsu CapitalreportedSeattle · $100K – $500K
How we know: a partner's Signal profile · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$10.6M disclosed across 2 rounds · 2014–2019
▶$6.1MraisedDec 2019 · 70 investors · PharmaceuticalsRule 506(b)
▶$6.1MraisedDec 2019 · 70 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Robert B. LinkeExecutive Officer, Director
- Joseph LovettDirector
- John BeairdDirector
- Ross BarrettDirector
- Offering amount
- $8.3M
- Amount sold
- $6.1M
- Sales commissions
- $3K
- Placement agents
- Witherspoon Partners
- First sale
- Sep 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4.5MraisedSep 2015 · 19 investors · PharmaceuticalsRule 506(b)
▶$4.5MraisedSep 2015 · 19 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Ross BarrettDirector
- Franz HeftiDirector
- John BeairdDirector
- Robert B. LinkeExecutive Officer, Director
- Joseph LovettDirector
- Offering amount
- $6.6M
- Amount sold
- $4.5M
- First sale
- Dec 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Embera NeuroTherapeutics do?
- Clinical-stage specialty pharma developing a combination drug to treat a range of addictions, licensed from LSU Health Sciences Center.
- Who are Embera NeuroTherapeutics's investors?
- Embera NeuroTherapeutics's investors include Innovation Catalyst, Keiretsu Forum, Louisiana Funds, Keiretsu Capital.
- How much funding has Embera NeuroTherapeutics raised?
- Embera NeuroTherapeutics has disclosed $10.6M raised across 2 rounds.
- Where is Embera NeuroTherapeutics headquartered?
- Embera NeuroTherapeutics is headquartered in Sudbury, US.